Literature DB >> 15652607

Porphyrias.

Raili Kauppinen1.   

Abstract

Seven different porphyrias form a group of inherited metabolic disorders, each resulting from a partial deficiency of a specific enzyme in the haem biosynthesis pathway. Clinically, the three most important entities are an acute porphyric attack and acute and chronic skin symptoms. Porphyrias are rare and sometimes misdiagnosed, because various symptoms and signs mimic other diseases. Once porphyria is suspected, biochemical analyses easily detect porphyrins and their precursors from blood, urine, or faeces. Mutation screening can be done at the quiescent phase of the disease. Pathogenetic mechanisms and clinical manifestations differ in individual porphyrias and most of them require a specific treatment. Early diagnosis and information about precipitating factors can diminish mortality and prevent subsequent attacks among patients with acute porphyrias, so mutation screening is recommended for family members.

Entities:  

Mesh:

Year:  2005        PMID: 15652607     DOI: 10.1016/S0140-6736(05)17744-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  51 in total

1.  Colon perforation secondary to porphyria.

Authors:  Kathryn E Thomas; Daniel Fletcher; Mina Mottahedeh
Journal:  Ann R Coll Surg Engl       Date:  2010-08-09       Impact factor: 1.891

2.  Feline porphyria associated with anemia, severe hepatic disease, and renal calculi.

Authors:  Jonathan J Schnier; Paul Hanna
Journal:  Can Vet J       Date:  2010-10       Impact factor: 1.008

3.  Regional Variation in Analytical Techniques used in the Diagnosis and Monitoring of Porphyria: a Case for Harmonisation?

Authors:  Christiaan W Sies; Virginia Cronin; Christopher M Florkowski; Jan Gill; Janine Grant; Victor Poulos; John Zoanetti
Journal:  Clin Biochem Rev       Date:  2015-05

4.  [Acute intermittent porphyria. A clinical chameleon: case study of a 40-year-old female patient].

Authors:  M Zimmermann; C Bonaccurso; C Valerius; G F Hamann
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

5.  [Laboratory tests and therapeutic strategies for the porphyrias].

Authors:  P Poblete-Gutiérrez; T Wiederholt; H F Merk; J Frank
Journal:  Hautarzt       Date:  2006-06       Impact factor: 0.751

Review 6.  [Hereditary photodermatoses].

Authors:  P Poblete-Gutiérrez; W H C Burgdorf; C Has; M Berneburg; J Frank
Journal:  Hautarzt       Date:  2006-12       Impact factor: 0.751

Review 7.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

8.  Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice.

Authors:  Carmen Unzu; Ana Sampedro; Itsaso Mauleón; Manuel Alegre; Stuart G Beattie; Rafael Enríquez de Salamanca; Jolanda Snapper; Jaap Twisk; Harald Petry; Gloria González-Aseguinolaza; Julio Artieda; María Sol Rodríguez-Pena; Jesús Prieto; Antonio Fontanellas
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

9.  Marked geographic aggregation of acute intermittent porphyria families carrying mutation Q180X in Venezuelan populations, with description of further mutations.

Authors:  Irene Paradisi; Sergio Arias
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

Review 10.  Peripheral neuropathy and inborn errors of metabolism in adults.

Authors:  F Sedel; C Barnerias; O Dubourg; I Desguerres; O Lyon-Caen; Jean-Marie Saudubray
Journal:  J Inherit Metab Dis       Date:  2007-09-21       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.